Results 11 to 20 of about 2,667,430 (358)
Sickle cell disease: progress towards combination drug therapy
British Journal of Haematology, 2021 Dr. John Herrick described the first clinical case of sickle cell anaemia (SCA) in the United States in 1910. Subsequently, four decades later, Ingram and colleagues characterized the A to T substitution in DNA producing the GAG to GTG codon and ...
B. Pace +2 more
semanticscholar +1 more source
Omadacycline Potentiates Clarithromycin Activity Against Mycobacterium abscessus
Frontiers in Pharmacology, 2021 Mycobacterium abscessus is a difficult respiratory pathogen to treat, when compared to other nontuberculus mycobacteria (NTM), due to its drug resistance.
Bui Thi Bich Hanh +7 more
doaj +1 more source
Independent Drug Action in Combination Therapy: Implications for Precision Oncology
Cancer Discovery, 2022 Combination therapies are superior to monotherapy for many cancers. This advantage was historically ascribed to the ability of combinations to address tumor heterogeneity, but synergistic interaction is now a common explanation as well as a design ...
D. Plana, A. Palmer, P. Sorger
semanticscholar +1 more source
Advancement of science, 2021 Nanomedicines with photodynamic therapy and reactive oxygen species (ROS)‐triggered drug release capabilities are promising for cancer therapy. However, most of the nanomedicines based on ROS‐responsive nanocarriers still suffer from serious ROS ...
Sheng Wang +8 more
semanticscholar +1 more source
Efficacy and Safety of Pioglitazone versus Glimepiride after Metformin and Alogliptin Combination Therapy: A Randomized, Open-Label, Multicenter, Parallel-Controlled Study [PDF]
Diabetes & Metabolism Journal, 2020 BackgroundThere is limited information regarding the optimal third-line therapy for managing type 2 diabetes mellitus (T2DM) that is inadequately controlled using dual combination therapy.
Jeong Mi Kim +12 more
doaj +1 more source
Basic principles of combination therapy: focus on drug-drug interaction
Кардиоваскулярная терапия и профилактика, 2021 The article is devoted to the issue of drug interactions in the combination regimens. Today, when drug therapy is the first-line approach for patients with noncommunicable diseases, and the world population ageing leads to an increase in the number of ...
S. Yu. Martsevich +2 more
doaj +1 more source
Nonalcoholic Fatty Liver Disease: A Drug Revolution Is Coming [PDF]
Diabetes & Metabolism Journal, 2020 The worldwide prevalence of non-alcoholic fatty liver disease is around 25%, and that of nonalcoholic steatohepatitis (NASH) ranges from 1.5% to 6.45%.
Soung Won Jeong
doaj +1 more source
MedComm – Biomaterials and Applications, 2023 Various nanocarriers have been explored to deliver drugs for combination therapy. However, most nanocarriers are composed of inert materials without contribution for improving the cancer therapeutic effect.
Jingqi Xin +3 more
doaj +1 more source
Metabolic Derangements with Anticonvulsants in Children with Generalised Tonic-clonic Epilepsy: A Cross-sectional Study [PDF]
Journal of Clinical and Diagnostic Research, 2023 Introduction: Epilepsy is one of the most prevalent noncommunicable neurologic conditions, accounting for significant disability and mortality. The effects of Antiepileptic Drugs (AEDs) on total cholesterol, triglycerides, High-Density Lipoprotein ...
Jyoti Sharma +3 more
doaj +1 more source
Understanding and targeting resistance mechanisms in cancer
MedComm, 2023 Resistance to cancer therapies has been a commonly observed phenomenon in clinical practice, which is one of the major causes of treatment failure and poor patient survival. The reduced responsiveness of cancer cells is a multifaceted phenomenon that can
Zi‐Ning Lei +6 more
doaj +1 more source